Retatrutide vs Semaglutide: What the TRANSCEND-T2D-2 Head-to-Head Trial Is Built to Test

When a new medicine is set against one you already know, the first question is usually: is it better? For retatrutide, which is still investigational, and semaglutide, the honest starting point is the trial design itself. This page explains what the head-to-head study measures and what it cannot tell you. It cites the public trial registry record, the European Medicines Agency's medicine summary and a published paper, not a company announcement, and it reports no result from this trial.

What is being compared

Semaglutide is the active ingredient in Ozempic, a once-weekly GLP-1 receptor agonist injection for adults with type 2 diabetes (EMA). Retatrutide is investigational: in TRANSCEND-T2D-2 it is listed as an experimental drug (also known as LY3437943), tested against semaglutide as the active comparator (ClinicalTrials.gov). It acts on three hormone receptors (GIP, GLP-1 and glucagon), according to the phase 2 paper in the New England Journal of Medicine (PubMed).

What TRANSCEND-T2D-2 is

The registry record (NCT06260722) sets out the design (ClinicalTrials.gov):

• Phase and type: a phase 3, randomized, open-label study sponsored by Eli Lilly and Company (ClinicalTrials.gov).
• Who takes part: adults with type 2 diabetes, an HbA1c between 7.0% and 10.5%, already on metformin with or without an SGLT2 inhibitor, and a BMI of at least 25 kg/m² (ClinicalTrials.gov).
• Arms: two retatrutide dose levels and one semaglutide arm, all once-weekly injections (ClinicalTrials.gov).
• Size and length: an estimated 1,250 participants over about 26 months (ClinicalTrials.gov).
• Main question: the change in HbA1c at week 80 (ClinicalTrials.gov).
• Other questions: percent change in body weight, the share of people losing at least 5%, 10% or 15% of body weight, blood fats and blood pressure (ClinicalTrials.gov).

What a head-to-head like this does and does not tell you

It is a diabetes study first. The primary outcome is blood sugar control, and weight change is a secondary outcome (ClinicalTrials.gov). Whatever it shows applies to adults with type 2 diabetes on metformin, which is not the same group as people taking a GLP-1 for weight alone.

The comparator dose matters. The registry summary names the semaglutide arm without stating its dose (ClinicalTrials.gov). When you see a comparison quoted, the comparator dose is the first detail worth checking.

Not everyone was eligible. People with type 1 diabetes, an eGFR below 45, pancreatitis, a recent heart attack or stroke, prior bariatric surgery, or weight-loss medication in the past 90 days were excluded (ClinicalTrials.gov).

The record is not finished. The study is active but not recruiting, primary completion was 27 August 2026, full completion is estimated for February 2027, and the registry shows no posted results (ClinicalTrials.gov). A company topline and a peer-reviewed paper are different things: the paper sets out the methods, full safety data and analysis for others to scrutinise.

What earlier retatrutide data showed

One published look at retatrutide comes from an earlier, different trial. In a phase 2, double-blind, placebo-controlled study of 338 adults with obesity, the authors reported average 48-week body weight changes ranging from about -8.7% to about -24.2% across the retatrutide dose groups, against -2.1% with placebo (PubMed). These are group averages from one trial, not a result any one person should expect. The most common side effects were gastrointestinal, dose-related and mostly mild to moderate (PubMed).

That trial used placebo, not semaglutide, in a different population over a shorter time, so it cannot be read as a preview of TRANSCEND-T2D-2. For the tirzepatide comparison, see our retatrutide vs tirzepatide explainer, and for the obesity programme, our TRIUMPH-1 page.

What semaglutide's own record looks like

Across five studies in over 4,000 patients, Ozempic lowered HbA1c by 1.2 to 1.8 percentage points over 10 to 13 months, according to the EMA (EMA). Its common side effects are diarrhoea, vomiting and nausea, usually mild to moderate and short-lived (EMA). The EMA also lists worsening of diabetic retinopathy as a risk under further investigation.

What changes today

Nothing about your current doses. A trial design, however interesting the drug, is not a reason to change anything on your own. If you are curious, the useful conversation with your prescriber is about what the trial measures, who it included and how to read news like this.

Meanwhile, the daily work stays the same. In Gila, you log each dose next to your daily Food Noise Score, so patterns between your medication and your days become visible. For a starting point, take the Food Noise Assessment.

Key Takeaways

• TRANSCEND-T2D-2 is a phase 3, open-label head-to-head of retatrutide against semaglutide in adults with type 2 diabetes (ClinicalTrials.gov).
• Its main question is blood sugar (HbA1c at week 80); weight is a secondary outcome (ClinicalTrials.gov).
• The registry shows no posted results yet (ClinicalTrials.gov).
• The published phase 2 retatrutide data come from an earlier, placebo-controlled trial in adults with obesity (PubMed).
• Nothing changes today: questions about your treatment belong in a conversation with your prescriber.

Keep what the medication starts

Editor: Sezen Soykut